Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Slightly Bullish +25

Gilead’s Arcus Pullback and Idvynso HIV Challenge Might Change The Case For Investing In GILD

AI-generated analysis

📉 Gilead discontinued continuation payments to Arcus Biosciences in April 2026, ending rights to several early-stage programs while retaining limited options on select assets like AB801 and AB598.

🧬 Merck’s newly approved Idvynso, an HIV regimen comparable to Gilead’s Biktarvy, has intensified competition in Gilead’s core profit-generating market.

🔍 Investors now view Gilead as requiring its HIV engine plus new launches such as Yeztugo and Livdelzi to offset pricing pressure and upcoming patent cliffs.

💊 Oncology is emerging as a crucial second pillar for Gilead as the company matures this diversified therapeutic area.

📅 The upcoming Q1 2026 earnings report and guidance update scheduled for May 7 will provide critical data on HIV trends and the status of remaining Arcus options.

📈 Simply Wall St projects Gilead Sciences to reach $33.6 billion in revenue and $10.9 billion in earnings by 2029, assuming 4.5% annual growth.

🔍 This growth projection results in a calculated fair value of $157.43 per share, representing an estimated 18% upside from the current price.

⚠️ Bearish analysts had already assumed slower growth (1.6% annually) and lower earnings figures by 2028 compared to consensus estimates.

📊 Management’s upcoming commentary on how it frames HIV competition and oncology progress will help determine if the company is meeting conservative or consensus expectations.

🧩 The combination of Arcus pullbacks and Idvynso’s entry may push Gilead’s earnings mix changes further into the long term than previously modeled.

💰 The article highlights that Gilead’s future valuation depends heavily on whether it can successfully navigate intensifying competition in its HIV portfolio.

🔮 Market consensus views on Gilead could shift significantly as new information regarding competitive threats and pipeline reductions is absorbed by investors.

⚖️ Simply Wall St notes that extraordinary investment returns often come from independent instincts rather than following the general market consensus.

📈 The analysis suggests a Snowflake visual tool is available to evaluate Gilead’s overall financial health, including its four key rewards and one warning sign.

⚙️ This article is presented as general commentary based on historical data and analyst forecasts, explicitly stating it is not intended as specific financial advice.

Bullish Signals
  • Gilead's pipeline projects $33.6 billion revenue and $10.9 billion earnings by 2029, representing significant long-term growth targets.
  • This trajectory requires approximately a $2.4 billion earnings increase from the current $8.5 billion level, signaling strong upside potential.
  • Uncover how Gilead Sciences' forecasts yield a $157.43 fair value, indicating an 18% upside to its current price.
  • New launches like Yeztugo and Livdelzi are positioned to offset pricing pressure and future patent cliffs in the HIV market.
  • Oncology is maturing into a real second pillar, providing diversification beyond Gilead's core HIV engine.
Risk Factors
  • Gilead ended option rights to several early-stage Arcus programs in April 2026 due to the lack of continuation payments, representing a contraction of its external pipeline portfolio.
  • Merck's newly approved Idvynso, demonstrated as non-inferior to Gilead's core HIV regimen Biktarvy, intensifies competitive pressure right as Gilead refines which external bets to retain.
  • Gilead's long-term financial projections of $10.9 billion earnings by 2029 now face a significant downside risk if investors adjust their growth assumptions down to the more bearish analyst consensus of just $8.1 billion by 2028.
  • The core HIV profit pool is at risk from heavier competition, potentially reshaping Gilead's long-term earnings mix before lenacapavib-based regimens can fully offset pricing pressure and patent cliffs.
Full Analysis
Gilead Sciences (GILD) faces a dual narrative shift as it navigates competitive pressures and portfolio adjustments. In April 2026, Gilead announced it will not make continuation payments to Arcus Biosciences for several early-stage programs, though options remain active on select assets like AB801, AB598, AB102, and a TNF inhibitor. Simultaneously, Merck's newly approved Idvynso, an HIV regimen deemed non-inferior to Gilead's core offering Biktarvy, has intensified competition in Gilead's primary revenue stream. Investors must now assess whether the upcoming first quarter 2026 results and guidance update on May 7 will signal if the company can maintain its financial trajectory despite these headwinds. The article analyzes how this specific portfolio reset impacts Gilead's long-term earnings projections, which currently project $33.6 billion in revenue and $10.9 billion in earnings by 2029, implying a $2.4 billion increase from today's $8.5 billion baseline. While the company projects 4.5% yearly revenue growth, some bearish analyst views already assume slower expansion, with estimates pointing to roughly $30.1 billion in revenue and $8.1 billion in earnings by 2028. The entry of Idvynso sharpens the risk regarding Gilead's HIV market share, potentially altering the long-term earnings mix as pricing pressure mounts against new launches like Yeztugo and Livdelzi. Ultimately, the investment case for GILE hinges on the belief that its diversified pipeline can offset these challenges by maturing oncology into a substantial second pillar and successfully defending its HIV engine. The company's guidance and management commentary on how to frame remaining options and oncology developments will be critical in determining if the stock follows the consensus path or shifts toward a more conservative outlook. The article concludes that while the Arcus decision is incremental, the competitive threat from Merck raises significant stakes around Gilead's most important catalyst, lenacapavib-based regimens.